Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors - Institut Curie Accéder directement au contenu
Article Dans Une Revue Immunity Année : 2016

Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors

Résumé

Inhibition of immune regulatory checkpoints, such as CTLA-4 and the PD-1-PD-L1 axis, is at the forefront of immunotherapy for cancers of various histological types. However, such immunotherapies fail to control neoplasia in a significant proportion of patients. Here, we review how a range of cancer-cell-autonomous cues, tumor-microenvironmental factors, and host-related influences might account for the heterogeneous responses and failures often encountered during therapies using immune-checkpoint blockade. Furthermore, we describe the emerging evidence of how the strong interrelationship between the immune system and the host microbiota can determine responses to cancer therapies, and we introduce a concept by which prior or concomitant modulation of the gut microbiome could optimize therapeutic outcomes upon immune-checkpoint blockade.

Dates et versions

hal-02639871 , version 1 (28-05-2020)

Identifiants

Citer

Jonathan M. Pitt, Marie Vétizou, Romain Daillere, Maria Paula Roberti, Takahiro Yamazaki, et al.. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity, 2016, 44 (6), pp.1255-1269. ⟨10.1016/j.immuni.2016.06.001⟩. ⟨hal-02639871⟩
89 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More